Table 1. Clinical characteristics of patients treated with anti-PD-1/PD-L1^*.

	Number	Percentage
Age	56 (median)	27–81 (range)
Gender
Male	16	53
Female	14	47
Stage
M1a	3	10
M1b	4	13
M1c	23	77
LDH elevated	12	40
Mutation
BRAF V600	6	20
NRAS Q61	7	23
BRAF/NRAS wild type	17†	57
Prior therapies	1 (median)	0–3 (range)
IL-2	5	20
Ipilimumab	14	47
BRAF±MEK inhibitor	4	13
Cytotoxic chemotherapy	5	17

^*Discovery cohort, n=30.

^†NRAS status unknown in two patients.